卡介苗治疗失败的治疗选择。 - Suppr

Suppr

超能文献

Treatment options for BCG failures.

作者信息

O'Donnell Michael A, Boehle Andreas

机构信息

Department of Urology, University of Iowa, 200 Hawkins Dr., 3 RCP, Iowa City, IA 52242-1089, USA.

出版信息

World J Urol. 2006 Nov;24(5):481-7. doi: 10.1007/s00345-006-0112-0.

DOI:10.1007/s00345-006-0112-0

PMID:17021823

Abstract

摘要

相似文献

Treatment options for BCG failures.卡介苗治疗失败的治疗选择。

World J Urol. 2006 Nov;24(5):481-7. doi: 10.1007/s00345-006-0112-0.

Radical cystectomy for BCG failure: has the timing improved in recent years?卡介苗治疗失败后的根治性膀胱切除术：近年来手术时机是否有所改善？

BJU Int. 2011 Jul;108(2):186. doi: 10.1111/j.1464-410X.2011.10439.x.

Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.卡介苗难治性非肌层浸润性膀胱癌的治疗

Arch Esp Urol. 2013 Nov;66(9):833-40.

Radical cystectomy for BCG failure: has the timing improved in recent years?根治性膀胱切除术治疗卡介苗失败：近年来时机是否有所改善？

BJU Int. 2011 Jul;108(2):182-5. doi: 10.1111/j.1464-410X.2010.09830.x. Epub 2010 Nov 10.

[Treatment of bladder tumors].[膀胱肿瘤的治疗]

Acta Urol Belg. 1999;67(1):6-10.

Valrubicin: an alternative to radical cystectomy for carcinoma in situ of the bladder.

Urol Nurs. 2001 Feb;21(1):30-1, 34-6.

Management of BCG failures in superficial bladder cancer: a review.浅表性膀胱癌中卡介苗治疗失败的管理：综述

Eur Urol. 2006 May;49(5):790-7. doi: 10.1016/j.eururo.2006.01.017. Epub 2006 Jan 24.

Management of high-risk non-muscle invasive bladder cancer.高危非肌层浸润性膀胱癌的管理

Minerva Urol Nefrol. 2012 Dec;64(4):255-60.

Management of BCG "Failures".卡介苗“接种失败”的管理

Eur Urol. 2006 May;49(5):779-80. doi: 10.1016/j.eururo.2006.03.006. Epub 2006 Mar 20.

BCG versus cytotoxic chemotherapy in the treatment of superficial bladder tumors.卡介苗与细胞毒性化疗治疗浅表性膀胱肿瘤的对比

Prog Clin Biol Res. 1992;378:55-7.

引用本文的文献

OncoTherad (MRB-CFI-1) Nanoimmunotherapy: A Promising Strategy to Treat Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer: Crosstalk among T-Cell CX3CR1, Immune Checkpoints, and the Toll-Like Receptor 4 Signaling Pathway.OncoTherad (MRB-CFI-1) 纳米免疫疗法：治疗卡介苗无反应性非肌肉浸润性膀胱癌的有前途策略：T 细胞 CX3CR1、免疫检查点和 Toll 样受体 4 信号通路之间的串扰。

Int J Mol Sci. 2023 Dec 15;24(24):17535. doi: 10.3390/ijms242417535.

BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.BCG 无应答性非肌肉浸润性膀胱癌：当前治疗现状与新型新兴分子靶点。

Int J Mol Sci. 2023 Aug 9;24(16):12596. doi: 10.3390/ijms241612596.

The Management of Bacillus Calmette-Guérin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article.高危非肌层浸润性膀胱癌中卡介苗（BCG）治疗失败的管理：一篇综述文章

Cureus. 2023 Jun 26;15(6):e40962. doi: 10.7759/cureus.40962. eCollection 2023 Jun.

Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments.非肌层浸润性膀胱癌的药物治疗：现状与未来治疗方法

Arch Pharmacol Ther. 2022;4(1):13-22.

A Transcriptional Signature of IL-2 Expanded Natural Killer Cells Predicts More Favorable Prognosis in Bladder Cancer.IL-2 扩增的自然杀伤细胞的转录特征可预测膀胱癌预后更佳。

Front Immunol. 2021 Nov 10;12:724107. doi: 10.3389/fimmu.2021.724107. eCollection 2021.

Emerging intravesical therapies for the management of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer: Charting a path forward.用于治疗卡介苗（BCG）无反应性非肌肉浸润性膀胱癌的新型膀胱内治疗方法：规划前进道路。

Can Urol Assoc J. 2020 Jun;14(6):204-213. doi: 10.5489/cuaj.6101.

Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage.当前非肌肉浸润性膀胱癌的临床试验：在慢性卡介苗短缺时代的迫切需求。

Curr Urol Rep. 2019 Nov 28;20(12):84. doi: 10.1007/s11934-019-0952-y.

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer.序贯膀胱内吉西他滨和多西他赛用于非肌层浸润性膀胱癌的挽救治疗

Bladder Cancer. 2015 Apr 30;1(1):65-72. doi: 10.3233/BLC-150008.

Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.非肌层浸润性膀胱癌膀胱内治疗的最新进展：如何、何时以及何种治疗。

World J Urol. 2019 Oct;37(10):2017-2029. doi: 10.1007/s00345-018-2591-1. Epub 2018 Dec 7.

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients.卡介苗无反应的非肌层浸润性膀胱癌患者的热灌注膀胱化疗

Bladder Cancer. 2018 Oct 29;4(4):395-401. doi: 10.3233/BLC-180191.

本文引用的文献

Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.卡介苗联合α-2B干扰素用于降低浅表性膀胱癌复发的全国多中心II期试验的最终结果。

Urol Oncol. 2006 Jul-Aug;24(4):344-8. doi: 10.1016/j.urolonc.2005.11.026.

Actual experience and future development of gemcitabine in superficial bladder cancer.

Ann Oncol. 2006 May;17 Suppl 5:v123-8. doi: 10.1093/annonc/mdj966.

Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.膀胱内注射吉西他滨治疗卡介苗难治性膀胱移行细胞癌的II期试验。

J Clin Oncol. 2006 Jun 20;24(18):2729-34. doi: 10.1200/JCO.2005.05.2720.

Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance.

Arch Ital Urol Androl. 2006 Mar;78(1):1-4.

Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study.膀胱内注射吉西他滨治疗卡介苗难治性膀胱T1G3移行细胞癌：一项初步研究。

Urol Int. 2006;76(2):106-11. doi: 10.1159/000090870.

Management of stage T1 tumors of the bladder: International Consensus Panel.膀胱T1期肿瘤的管理：国际共识小组

Urology. 2005 Dec;66(6 Suppl 1):108-25. doi: 10.1016/j.urology.2005.08.066.

High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder.高级别Ta期膀胱尿路上皮癌和膀胱原位癌

Urology. 2005 Dec;66(6 Suppl 1):90-107. doi: 10.1016/j.urology.2005.06.135.

Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.膀胱癌的预后标志物：膀胱癌肿瘤标志物国际共识小组

Urology. 2005 Dec;66(6 Suppl 1):64-74. doi: 10.1016/j.urology.2005.08.065.

Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.膀胱内注射吉西他滨治疗卡介苗难治性膀胱原位癌的药代动力学研究

Urol Int. 2005;75(4):309-13. doi: 10.1159/000089164.

Intravesical bacillus Calmette-Guèrin therapy: experience with a reduced dwell-time in patients with pronounced side-effects.

BJU Int. 2005 Dec;96(9):1290-3. doi: 10.1111/j.1464-410X.2005.05817.x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验